Anticancer Drug-Related Nonvalvular Atrial Fibrillation: Challenges in Management and Antithrombotic Strategies

Abstract

Cancer patients may experience nonvalvular atrial fibrillation (AF) as a manifestation of cardiotoxicity. AF may be a direct effect of a neoplasm or, more often, appear as a postsurgical complication, especially after thoracic surgery. AF may also develop as a consequence of anticancer therapy (chemotherapy or radiotherapy), a condition probably underestimated. Cancer patients with AF require a multidisciplinary approach involving oncologists/hematologists, cardiologists, and coagulation experts. An echocardiogram should be performed to detect possible abnormalities of left ventricular systolic and diastolic function, as well as left atrial dilation and the existence of valvular heart disease, to determine pretest probability of sinus rhythm restoration, and identify the best treatment. The choice of antiarrhythmic treatment in cancer patients may be difficult because scanty information is available on the interactions between anticancer agents and antiarrhythmic drugs. A careful evaluation of the antithrombotic strategy with the best efficacy/safety ratio is always needed. The use of vitamin K antagonists (VKAs) may be problematic because of the unpredictable therapeutic response and high bleeding risk in patients with active cancer who are undergoing chemotherapy and who may experience thrombocytopenia and changes in renal or hepatic function. Low molecular weight heparins (in particular for short and intermediate periods) and non-VKA oral anticoagulants (NOACs) should be preferred. However, the possible pharmacological interactions of NOACs with both anticancer and antiarrhythmic drugs should be considered. Based on all these considerations, antiarrhythmic and anticoagulant therapy for AF should be tailored individually for each patient.

Keywords

atrial fibrillation - cancer - drug interaction - stroke - anticoagulants

• References

• 1 Kirchhof P, Benussi S, Kotecha D. , et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
• 2 Zamorano JL. Specific risk of atrial fibrillation and stroke in oncology patients. Eur Heart J 2016; 37 (36) 2747-2748
• 3 Zamorano JL, Lancellotti P, Rodriguez Muñoz D. , et al; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (36) 2768-2801
• 4 Hu YF, Liu CJ, Chang PM. , et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 2013; 165 (02) 355-357
• 5 Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014; 63 (10) 945-953
• 6 Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009; 11 (12) 1579-1586
• 7 Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38 (02) 129-152
• 8 Lardaro T, Self WH, Barrett TW. Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer. Am J Emerg Med 2015; 33 (10) 1483-1488
• 9 Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013; 34 (15) 1102-1111
• 10 Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015; 12 (04) 230-243
• 11 Dindogru A, Barcos M, Henderson ES, Wallace Jr HJ. Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol 1978; 5 (01) 65-71
• 12 Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. South Med J 2007; 100 (03) 262-265
• 13 Pfister DG, Su YB, Kraus DH. , et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24 (07) 1072-1078
• 14 Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol 1991; 9 (01) 192-193
• 15 Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988; 13 (01) 41-46
• 16 Petrella V, Alciato P, Cantone PA, Fico D, Gagliardini R. High-frequency atrial arrhythmia induced by a cisplatin-etoposide combination. [in Italian]. Minerva Med 1989; 80 (03) 305-307
• 17 Lara Jr PN, Mack PC, Synold T. , et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005; 11 (12) 4444-4450
• 18 Tomkowski WZ, Wiśniewska J, Szturmowicz M. , et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 2004; 12 (01) 53-57
• 19 Richards WG, Zellos L, Bueno R. , et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24 (10) 1561-1567
• 20 Bischiniotis TS, Lafaras CT, Platogiannis DN, Moldovan L, Barbetakis NG, Katseas GP. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol 2005; 46 (05) 324-329
• 21 Quezado ZM, Wilson WH, Cunnion RE. , et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118 (01) 31-36
• 22 Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5 (02) 91-98
• 23 Moreau P, Milpied N, Mahé B. , et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23 (10) 1003-1006
• 24 Olivieri A, Corvatta L, Montanari M. , et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998; 21 (10) 1049-1053
• 25 Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011; 34 (06) 356-359
• 26 Phillips GL, Meisenberg B, Reece DE. , et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004; 10 (07) 473-483
• 27 Mileshkin LR, Seymour JF, Wolf MM. , et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005; 46 (11) 1575-1579
• 28 Jeremic B, Jevremovic S, Djuric L, Mijatovic L. Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990; 2 (04) 264-267
• 29 Sørensen HT, Christensen S, Mehnert F. , et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336 (7648): 813-816
• 30 McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124 (25) 3829-3830
• 31 Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol 2016; 91 (06) E312-E313
• 32 Chanan-Khan A, Cramer P, Demirkan F. , et al; HELIOS investigators Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17 (02) 200-211
• 33 Foran JM, Rohatiner AZ, Cunningham D. , et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18 (02) 317-324
• 34 Dutcher JP, Fisher RI, Weiss G. , et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3 (03) 157-162
• 35 Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007; 18 (11) 1906-1907
• 36 Rini B, Redman B, Garcia JA. , et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol 2014; 25 (09) 1794-1799
• 37 Cassinotti A, Massari A, Ferrara E. , et al. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol 2007; 63 (09) 875-878
• 38 Dodd HJ, Tatnall FM, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J (Clin Res Ed) 1985; 291 (6497): 706
• 39 Murphy G, Fulton RA, Keegan DA. Fast atrial fibrillation induced by azathioprine. Br Med J (Clin Res Ed) 1985; 291 (6501): 1049
• 40 Riccioni G, Bucciarelli V, Di Ilio E. , et al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature. Int J Immunopathol Pharmacol 2011; 24 (01) 247-249
• 41 Palma M, Mancuso A, Grifalchi F, Lugini A, Pizzardi N, Cortesi E. Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002; 88 (06) 527-529
• 42 Zingler VC, Nabauer M, Jahn K. , et al. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005; 54 (01) 28-33
• 43 Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J 2007; 13 (02) 211-212
• 44 Mery B, Guichard JB, Guy JB. , et al. Atrial fibrillation in cancer patients: hindsight, insight and foresight. Int J Cardiol 2017; 240: 196-202
• 45 Asnani A, Manning A, Mansour M. , et al. Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology 2017; 3: 2
• 46 Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003; 21 (19) 3609-3615
• 47 Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016; 30 (01) 11-19
• 48 des Guetz G, Uzzan B, Chouahnia K, Morère JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 2011; 6 (04) 197-202
• 49 Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014; 19 (01) 82-93
• 50 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
• 51 Lee YJ, Park JK, Uhm JS. , et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol 2016; 203: 372-378
• 52 Ambrus DB, Reisman JI, Rose AJ. The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. Thromb Res 2016; 144: 21-26
• 53 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
• 54 Fitzpatrick T, Carrier M, Le Gal G. Cancer, atrial fibrillation, and stroke. Thromb Res 2017; 155: 101-105
• 55 Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114 (02) 79-102
• 56 Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 2009; 102 (02) 258-267
• 57 Larsen TB, Nielsen PB, Skjøth F, Rasmussen LH, Lip GY. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014; 9 (12) e114445
• 58 Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 2017; 6 (06) 1165-1172
• 59 Heidbuchel H, Verhamme P, Alings M. , et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10) 1467-1507
• 60 Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010; 64 (07) 956-967
• 61 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
• 62 de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther 2016; 100 (05) 548-557
• 63 Coltelli L, Fontana A, Lucchesi S. , et al. Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. Breast 2017; 31: 186-191
• 64 Plana JC, Galderisi M, Barac A. , et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15 (10) 1063-1093
• 65 Gottlieb M, Khishfe B. Idarucizumab for the reversal of dabigatran. Ann Emerg Med 2017; 69 (05) 554-558
• 66 Cappato R, Ezekowitz MD, Klein AL. , et al; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35 (47) 3346-3355
• 67 Lip GY, Merino J, Ezekowitz M. , et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J 2015; 169 (05) 597-604.e5
• 68 Kosmas C, Kallistratos MS, Kopterides P. , et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134 (01) 75-82